North China Pharmaceutical Group Corp. (NCPC) is a leading pharmaceutical manufacturer in China. NCPC, in its early days, was one of the key construction projects during Chinese First Five-Year Plan. After fiver years of construction from the foundation date in June 1953, the successful operation started in June 1958. Being one of the world leading antibiotic producers both in technology and production with 50 years development, pharmaceutical industry in key economic indexes, ranking one of the Top500 Enterprises and the best profit-makers in China. By the end of 2008, the total assets is USD2.5 billion,number of employees 18500. In 2008, NCPC achieved domestic sales revenue USD 700million and export salesUSD177million. Sticking to the spirit of “Service for Life “, NCPC is willing to build bright future for all the people.
NCPC now has 29 subsidiaries. Among which North China Pharmaceutical Co., Ltd. is a listed company at Shanghai Stock Exchange with 59.87% of shaires held by NCPC. NCPC is one of the four groups of the candidate enterprises approved by China Securities Regulatory Commission for overseas listing. Keeping in close cooperation with foreign companies and institutions, NCPC has established 16 joint ventures and cooperative ventures.
NCPC’s main businesses covers: over 590 varieties, ranging from antibiotic bulks and formulations, vitamins and nutrition products, biotech products, immunosuppressant, and pesticide to veterinary drugs; the annual sales volume for antibiotic bulks is up to 8,000 tons, for vitamins is 23,000 tons, for antibiotic intermediates is up to 5,000 tons, and for formulations amounts to 4.1 billion vials/tablets/capsules; and the main products now occupies a considerably big share of the domestic market. The output and sales volume of Penicillin, Amoxicillin, and Streptomycin sulfate, Cefradine, 7-ADCA, Vitamin C and Vitamin B12 are ranking in the forefront of the world.
Antibiotics are still the core products in NCPC. During her 50 years, NCPC has accumulated its own advantages in antibiotics field, which ensures both its production scale and technology to take lead at home. Dozens of new antibiotics have been developed. At present, NCPC is the second largest penicillin enterprise of the world, and is the largest manufacture of Penicillin, Amoxicillin, Streptomycin, Cefradine, 6-APA and 7-ADCA in China.
Development of bio-pharmacy is NCPC’s new strategic orientation. Utilizing its technological advantages accumulated in the field of traditional fermentation (antibiotics) since 1984, NCPC has initiated modern biotech research and set up a bio-tech drugs development system involving new products R&D, pilot scale and industrialization. At present G-CSF, GM-CSF, EPO and Gene tic Engineering Hepatitis B Vaccines have been launched into the market..
QC & QA
NCPC began to promote TQM in early 1980s. Systematic trainings for quality awareness have been carried out, and about 270 people have been awarded the State Quality Professional Qualification Certificates. In order to satisfy customers’ requirements, an effective quality management system has been established after continuous improvement activitives. In 1986, NCPC became first enterprise in pharmaceutical sector awarded the “National Quality Management Prize”;
Nowadays, 5 products have been entitled as the “National Excellent Product Prize”, 40 products have won prizes in national or provincial quality appraisals. 49 products manufactured according to “International Standard or Overseas Advanced Standard” are certified for standards adoption ,ivermectin, lincomycin hydrochloride, amphotericin B and oxytetracycline have been approved by FDA，and other 10 products (Penicillin V Potassium etc.) have been certified with CEP certificates. NCPC insists on organizing production strictly in compliance with international standards and overseas advanced standards. Main products are certified by standards adoption. NCPC has established its own internal quality control standards, which are much stricter than mandatory standards.
NCPC attaches much importance to supporting and motivating its employees participation in quality improvement. Among them “QC Group” activities have been carried out for over 20 years, bringing out significant economic benefits for the company.
R & D
New drugs is the core success factor in the competition among pharmaceutical enterprises. With a market-oriented initiative, NCPC keeps increasing investment in technological innovation in order to strengthen its new drugs R&D system, and to accelerate new drugs development with self-own intellectual property rights.
NCPC has strong capability to conduct researche and development projects and has been taking the lead in China in developing dozens of new products, such as Kasugamycin, Bleomycin, Amphotericin B, Lincomycin, Clindamycin, and Clindamycin phosphate, Norvancomycin, Mecobalamin and EPO.
Former NCPC Antibiotics Research Institute was restructured into New Drug R&D Centre in 1991, which was the first Enterprise Technology Centre in China’s pharmaceutical industry，recognized by the state.
There are more than 300 excellent experts and talented researchers in the centre ,equipped with advanced laboratory instrument and complete pilot facilities to constitute a system network for new drugs R&D and commercialization . Thanks to long term efforts and huge investments, there have been new drugs have launched in the market every year . Meanwhile, NCPC also cooperates with many well-known research institutions at home and aboard in introduce various technical and research resources and form an innovation alliance among industrial,academic and research forces.
NCPC new drugs R&D mode is now being transformed from “Imitation” into “Innovation”. Since mid-1980s, platform technologies for new drugs development have been gradually introduced and studied through cooperation with research institutes, thus a new drug development system belonging to its own has started to take its shape.